Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
This is the complete answer, not a partial one — the list is never padded.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Joshua Brumm | $554,167 | — | $2,381,440 | $9,635,227 | $546,000 | — | — | $13,116,834 |
| Chief Executive Officer & Director | ||||||||
| Jonathan McNeill | 435,417 | — | 1,163,619 | 4,683,542 | 321,750 | — | — | 6,604,328 |
| Chief Operating Officer & President | ||||||||
| Ellie Im | 401,250 | — | 281,347 | 2,666,923 | 312,975 | — | — | 3,662,495 |
| Chief Medical Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Joshua Brumm | $13,116,834 | — | — | — |
| Jonathan McNeill | 6,604,328 | — | — | — |
| Ellie Im | 3,662,495 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Joshua Brumm | RSU | 268,400 | — | $3,183,224 |
| Jonathan McNeill | RSU | 134,200 | — | 1,591,612 |
| Joshua Brumm | RSU | 55,117 | — | 653,688 |
| Jonathan McNeill | RSU | 25,507 | — | 302,513 |
| Ellie Im | RSU | 21,298 | — | 252,594 |
| Joshua Brumm | Option | 345,672 | 13.17 | — |
| Joshua Brumm | Option | 180,467 | 13.21 | — |
| Jonathan McNeill | Option | 172,836 | 13.17 | — |
| Jonathan McNeill | Option | 78,029 | 13.21 | — |
| Ellie Im | Option | 65,190 | 13.21 | — |
Compensation positioning is used to attract and retain key employees for the Company’s continued success and growth, balancing internal and external alignment while considering strategy, shareholder feedback, tenure, performance, and criticality.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | — |
| Anti-pledging | — |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-02 | 18,346,099 | 300,217 | 876 | 98.39% | Passed |
| 2024 | 2024-05-01 | 35,292,808 | 1,881,276 | 75,670 | 94.94% | Passed |
| 2023 | 2023-05-19 | 36,116,823 | 435,570 | 112,283 | 98.81% | Passed |
| 2022 | 2022-05-18 | 27,132,991 | 1,035,554 | 88,527 | 96.32% | Passed |
| 2021 | 2021-05-18 | 31,828,920 | 380,710 | 611,792 | 98.82% | Passed |
| 2020 | 2020-05-22 | 34,250,221 | 1,056,258 | 22,197 | 97.01% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-02 | 98.39%a |
| 2024 | 2024-05-01 | 94.94%b |
| 2023 | 2023-05-19 | 98.81%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 1,000 : 1 |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Jonathan ViolinIndependent · Nominating and Corporate Governance Committee | $24,812 | $192,566 | $106,923 | — | $150,000 | $474,301 |
| Jonathan Violin, Ph.DNot independent · Nominating · Nominating and Corporate Governance | 24,812 | 192,566 | 106,923 | — | 150,000 | 474,301 |
| David LubnerIndependent · Audit Committee · Compensation Committee (Chair) · Nominating and Corporate Governance Committee | 34,569 | 0 | 260,422 | — | 0 | 294,991 |
| Peter HarwinIndependent · Board Chair · Nominating and Corporate Governance Committee (Chair) | 44,652 | 0 | 106,923 | — | 0 | 151,575 |
| Alexandra BalcomIndependent · Audit Committee (Chair) · Compensation Committee | 33,543 | 0 | 106,923 | — | 0 | 140,466 |
| Susan Moran, M.D., MSCEIndependent · Audit · Compensation | 30,041 | 0 | 106,923 | — | 0 | 136,964 |
| Joshua BrummEmployee director | — | — | — | — | — | 0 |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 7,500 / 6,000 / 5,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $192,429 |
| Equity awards (grant-date value) | $385,132 |
| All other compensation | $300,000 |
| Total cost of the board | $877,561 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Crescent Biopharma | 2025 | Joshua Brumm | $554,167 | $2,381,440 | $9,635,227 | $546,000 | $13,116,834 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Joshua Brumm | DEF 14A | 2026-04-21 | 0001628280-26-026282 | Section “Executive Compensation”. As printed: 13,116,834. Filing ↗ |
| 2 | Section 01, Jonathan McNeill | DEF 14A | 2026-04-21 | 0001628280-26-026282 | Section “Executive Compensation”. As printed: 6,604,328. Filing ↗ |
| 3 | Section 01, Ellie Im | DEF 14A | 2026-04-21 | 0001628280-26-026282 | Section “Executive Compensation”. As printed: 3,662,495. Filing ↗ |
| 4 | Section 07, pay ratio | DEF 14A | 2026-04-21 | 0001628280-26-026282 | Section “CEO Pay Ratio”. As printed: 1000 : 1. Filing ↗ |
| 5 | Section 08, Jonathan Violin | DEF 14A | 2026-04-21 | 0001628280-26-026282 | Section “Director Compensation”. As printed: 474,301. Filing ↗ |
| 6 | Section 08, Jonathan Violin, Ph.D | DEF 14A | 2026-04-21 | 0001628280-26-026282 | Section “Director Compensation”. As printed: 474,301. Filing ↗ |
| 7 | Section 08, David Lubner | DEF 14A | 2026-04-21 | 0001628280-26-026282 | Section “Director Compensation”. As printed: 294,991. Filing ↗ |
| 8 | Section 08, Peter Harwin | DEF 14A | 2026-04-21 | 0001628280-26-026282 | Section “Director Compensation”. As printed: 151,575. Filing ↗ |
| 9 | Section 08, Alexandra Balcom | DEF 14A | 2026-04-21 | 0001628280-26-026282 | Section “Director Compensation”. As printed: 140,466. Filing ↗ |
| 10 | Section 08, Susan Moran, M.D., MSCE | DEF 14A | 2026-04-21 | 0001628280-26-026282 | Section “Director Compensation”. As printed: 136,964. Filing ↗ |
| 11 | Section 08, Joshua Brumm | DEF 14A | 2026-04-21 | 0001628280-26-026282 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 12 | Section 06, 2026 vote | Form 8-K | 2026-06-03 | 0001628280-26-040051 | Item 5.07 · say-on-pay result. As reported: 98.39% (votes for as printed: 18,346,099). Filing ↗ |
| 13 | Section 06, 2024 vote | Form 8-K | 2024-05-02 | 0001558370-24-006459 | Item 5.07 · say-on-pay result. As reported: 94.94% (votes for as printed: 35,292,808). Filing ↗ |
| 14 | Section 06, 2023 vote | Form 8-K | 2023-05-22 | 0001558370-23-010301 | Item 5.07 · say-on-pay result. As reported: 98.81% (votes for as printed: 36,116,823). Filing ↗ |
| 15 | Section 09b board cost (computed) | Computed | — | computed | Cash 192,429 + equity 385,132 + all other 300,000 = 877,561, summed across the director compensation table rows.machine: formula: Σ = 877,561 |
| 16 | Crescent Biopharma (subject), Section 10b CEO total | DEF 14A | 2026-04-21 | 0001628280-26-026282 | CEO total compensation as printed in Crescent Biopharma's own proxy. As printed: 13,116,834. Filing ↗ |